If you have been reading about receptor agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
== Description == Diabetes is a well known chronic disease that affects many individuals of all ages worldwide. There are many subtypes including Type 1, Type 2, gestational diabetes, maturity-onset diabetes of the young (MODY), neonatal diabetes, with Type 1 and Type 2 being the most common. All types of diabetes should be controlled as uncontrolled diabetes can cause many complications. Blood glucose levels that are too low (hypoglycemia) or too high (hyperglycemia) can cause both acute and chronic problems. Uncontrolled diabetes can harm the inner lining of blood vessels, which affects the ability of blood to deliver nutrients and oxygen to organs throughout the body. By causing damage to blood vessels, diabetes is associated with an increased risk of macrovascular (large blood vessel) conditions such as stroke and heart disease (heart attacks). Diabetes is also associated with microvascular (small blood vessel) complications to organs such as the eyes (diabetic retinopathy) and the kidneys (diabetic nephropathy). In addition to maintaining adequate blood sugar levels in the body, control of other risk factors that contribute to complications such as smoking, alcohol use, excessive weight, high blood pressure, and high cholesterol are also very important. Often, the recommended treatment for diabetes mellitus is a combination of lifestyle changes such as increasing exercise and healthy eating, along with medications to help control the blood glucose levels in the long term.
=== Reactions of strained alkenes === Strained alkenes also use strain-relief as a driving force that allows for their participation in click reactions. Trans-cycloalkenes (usually cyclooctenes) and other strained alkenes such as oxanorbornadiene react in click reactions with a number of partners including azides, tetrazines, and tetrazoles. These reaction partners may interact specifically with the strained alkene, staying bioorthogonal to endogenous alkenes found in lipids, fatty acids, cofactors, and other natural products.
== Treatment == Silicosis is a permanent disease with no cure. Treatment options currently available focus on alleviating the symptoms and preventing any further progress of the condition. These include:
Sources: en.wikipedia.org
=== Hurricane Andrew === In August 1992, the 82nd Airborne deployed a task force to the hurricane-ravaged area of South Florida to provide humanitarian assistance following Hurricane Andrew. For more than 30 days, troopers provided food, shelter and medical attention to the Florida population as part of the US military Domestic Emergency Planning System. The 82nd was part of over 20,000 Army, Navy, Air Force, Marine, Coast Guard and an additional 6200 National Guard troops deployed for the disaster. They also provided security and a sense of safety for the victims of the storm who were without power, doors, windows and in many cases roofs.
The zangfu (脏腑; 臟腑; zàngfǔ) are the collective name of eleven entities (similar to organs) that constitute the centre piece of TCM's systematization of bodily functions. The term zang refers to the five considered to be yin in nature – Heart, Liver, Spleen, Lung, Kidney – while fu refers to the six associated with yang – Small Intestine, Large Intestine, Gallbladder, Urinary Bladder, Stomach and San Jiao. Despite having the names of organs, they are only loosely tied to (rudimentary) anatomical assumptions. Instead, they are primarily understood to be certain "functions" of the body. To highlight the fact that they are not equivalent to anatomical organs, their names are usually capitalized. The zang's essential functions consist in production and storage of qi and xuě; they are said to regulate digestion, breathing, water metabolism, the musculoskeletal system, the skin, the sense organs, aging, emotional processes, and mental activity, among other structures and processes. The fǔ organs' main purpose is merely to transmit and digest (傳化; chuán-huà) substances such as waste and food. Since their concept was developed on the basis of Wǔ Xíng philosophy, each zàng is paired with a fǔ, and each zàng-fǔ pair is assigned to one of five elemental qualities (i.e., the Five Elements or Five Phases). These correspondences are stipulated as:
The Type IV civilization would still be vulnerable to some cosmic threats, while the Type V civilization would be technically immortal, as no cosmic catastrophe could reach it. The Kardashev scale can be a relevant tool for preventing catastrophes, whether human or natural, according to Richard Wilson, who relates this scale to the power of destruction, in TNT. A Type I civilization would use 25 megatons per second of equivalent TNT, a Type II civilization 4×1019 times more (4 billion hydrogen bombs per second), while a Type III civilization would use 1011 times more.
Sources: en.wikipedia.org
=== „Dein Name“ (2015) === Considering that Kermani described this novel in his Frankfurt lectures on poetics as a failed attempt to capture the specific shock of death in a conventional literary form, we have to read this assessment against the backdrop of his extensive work on his major novel Dein Name [Your Name], which was originally conceived as a book of the dead and is committed to a different kind of remembrance of the dead. With its 1,229 densely printed pages, Dein Name is Kermani's longest work. Classified by many critics as his magnum opus, it represents one of the most original works of autofiction in contemporary literature. The text is narrated by a character named Navid Kermani, who shares many, but not all, biographical details with the author. The narrative combines the styles of, among other genres, a diary, a relationship and family novel, a travel reportage, an internet blog, an epistolary or text messages novel, a poetological and scholarly treatise, a political essay, and—presented as its core—obituary-like commemorative texts. These short texts are dedicated to individuals almost all of whom were close to the author and whom he lost during the period between June 8, 2006, and June 11, 2011, while he was working on this novel. On a second narrative level, the novel tells the story of its own fashioning, not only in terms of poetics and the writing process, but in terms of the author-character’s entire life.
== European Union == Source: The Principles of GLP help ensure the quality and accuracy of data in chemical testing, and help prevent scientific fraud, as adopted by the European Union (EU). European GLP Regulations and Directives also apply to European Economic Area (EEA) member states which include Iceland, Liechtenstein, and Norway. GLP principles govern the laboratory safety testing of substances in various products, mandated by product-specific legislation in the EU/EEA. Directive 2004/9/EC mandates EU/EEA countries to designate GLP inspection authorities and includes requirements for reporting and mutual acceptance of data within the internal market. Annex I of the Directive incorporates OECD Revised Guides for Compliance Monitoring Procedures for GLP, along with OECD Guidance for the Conduct of Test Facility Inspections and Study Audits. It ensures compliance with these guidelines during laboratory inspections and study audits. This directive replaced Directive 88/320/EEC as of 11 March 2004. Directive 2004/10/EC, the second core EU GLP Directive, harmonizes laws and administrative provisions for applying GLP principles and verifying their implementation in chemical substance tests. It includes GLP principles in Annex I and requires EU/EEA countries to ensure that laboratories conducting safety studies on chemical products comply with OECD GLP principles. It replaces Directive 87/18/EEC.
== Research history == GLP-1 was first described 1979 by a research group of Werner Creutzfeldt in Göttingen. Also Jens Juul Holst worked in this area. In the early 1980s, Richard Goodman and P. Kay Lund were postdoctoral researchers working in Joel Habener's laboratory at Massachusetts General Hospital. Starting in 1979, Goodman harvested DNA from American anglerfish islet cells and spliced the DNA into bacteria to find the gene for somatostatin; Lund then joined the Habener laboratory and used Goodman's bacteria to identify the gene for glucagon. In 1982, they published their discovery that the gene for proglucagon actually codes for three peptides, namely glucagon and two novel peptides. Those two novel peptides were later isolated, identified, and investigated by other researchers, and are now known as glucagon-like peptide-1 and glucagon-like peptide-2. In the 1980s, Svetlana Mojsov worked on the identification of GLP-1 at Massachusetts General Hospital, where she was head of a peptide synthesis facility. To try to identify whether a specific fragment of GLP-q was an incretin, Mojsov created an incretin-antibody and developed ways to track its presence. She identified that a stretch of 31 amino acids in the GLP-1 was an incretin. Mojsov and her collaborators Daniel J. Drucker and Habener showed that small quantities of laboratory-synthesized GLP-1 could trigger insulin. Mojsov fought to have her name included in patents, with Mass General eventually agreeing to amend four patents to include her name. She received her one-third of drug royalties for one year.
Meiri (2022) questioned the reliability of the estimates, citing uncertainty in metabolic rate, body size, sex and age-specific survival rates, habitat requirements and range size variability as shortcomings Marshall et al. did not take into account. The authors of the original publication replied that while they agree that their reported uncertainties were probably too small, their framework is flexible enough to accommodate uncerainty in physiology, and that their calculations do not depend on short-term changes but rather on long-term averages. Finally, they remark that they did estimate the range of reasonable survivorship curves and that they did include uncertainty in the time of onset of sexual maturity and in the growth curve by incorporating the uncertainty in the maximum body mass.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.